HIV Treatment Drugs 2026: Every Approved Regimen

The preferred HIV treatment drugs for most adults in 2026 are Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) and Dovato (dolutegravir/lamivudine) — both single-tablet regimens taken once daily. For patients who prefer not to take daily pills, Cabenuva (cabotegravir + rilpivirine injection) given monthly or every two months is a DHHS-preferred injectable alternative. All three are integrase inhibitor-based regimens. Alternative options include Symtuza and Odefsey for patients with specific clinical needs. Long-acting injectable lenacapavir (Sunlenca) is approved for treatment-experienced patients with drug-resistant HIV and is being studied for broader use.

For most treatment-naive adults, Biktarvy is widely considered the benchmark HIV medication in 2026 — it has the highest genetic barrier to resistance of any single-tablet regimen, requires no baseline resistance testing, has no food requirement, and achieved over 98% viral suppression at 5 years in clinical trials with a discontinuation rate below 1% due to side effects. Dovato is a strong alternative offering a 2-drug regimen with less long-term drug exposure, but it requires baseline resistance testing and is not suitable for all patients. The “best” drug for any individual depends on their specific clinical situation — viral load at diagnosis, co-infections, co-medications, and personal preferences all matter.

Biktarvy is used to treat HIV-1 infection in adults and pediatric patients weighing at least 14 kg. It is approved for treatment-naive adults (those starting HIV treatment for the first time) and for virologically stable adults switching from another regimen. It is not approved for HIV prevention (PrEP). Biktarvy contains three antiretroviral agents: bictegravir (an INSTI), emtricitabine (an NRTI), and tenofovir alafenamide (an NRTI). For a complete overview of its indications and clinical data, see what is Biktarvy used for.

Not yet approved, but lenacapavir (Sunlenca) comes close — it is a twice-yearly subcutaneous injection currently approved for treatment-experienced patients with drug-resistant HIV. Clinical trials are underway evaluating twice-yearly lenacapavir as both a treatment option for treatment-naive patients and as PrEP. The PURPOSE 1 and PURPOSE 2 trials studying lenacapavir for PrEP showed exceptional results, with near-complete prevention of HIV acquisition. A truly once-yearly HIV treatment option may follow in the next few years pending regulatory approvals.

Both are DHHS-preferred single-tablet regimens for HIV treatment-naive adults, but they differ in several important ways. Biktarvy is a 3-drug regimen (BIC/FTC/TAF) with the highest resistance barrier of any STR, no food requirement, and no baseline resistance testing requirement. Dovato is a 2-drug regimen (DTG/3TC) with less total drug exposure — an advantage for minimizing long-term drug effects — but it requires baseline resistance testing, cannot be used in hepatitis B co-infection, and is not recommended when baseline viral load exceeds 500,000 copies/mL. In direct comparisons, both achieved similar viral suppression rates at 48 weeks and beyond.

HIV drugs work by blocking specific steps in the HIV replication cycle. HIV must enter a CD4 T-cell, convert its RNA genome to DNA (reverse transcription), insert that DNA into the host cell’s genome (integration), and then produce and mature new viral particles. Different drug classes block different steps: NRTIs block reverse transcription, INSTIs block integration, protease inhibitors block viral protein maturation, and entry/attachment inhibitors block cell entry. Using drugs from multiple classes simultaneously makes it virtually impossible for HIV to replicate, because the virus would need to develop resistance mutations at multiple steps at once. For a detailed explanation of each class, see what is antiretroviral therapy.